ClinicalTrials.gg

Program

AB-001

Also written as “AB001” and “AB001 patch”.

Its studies are mostly in Low Back Pain · Prostatic Neoplasms, led by 2 companies.

Furthest: phase 2, since Apr 30, 20153 company-led studies, 1 open or runningNext primary completion: Nov 3, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Frontier Biotechnologies20 open or runningphase 2since Apr 30, 2015Apr 30, 2015none ahead
ARTBIO11 open or runningphase 1since Jul 21, 2025Jul 21, 2025Nov 3, 2027phase 1 · NCT07214961

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 30, 2015First study: phase 2 study in Chronic Low Back PainNew to Frontier BiotechnologiesFrontier Biotechnologies · NCT02436824 · 146 enrolled · United States
  2. Jun 19, 2019Phase 1 study in Chronic Low Back PainFrontier Biotechnologies · NCT03997734 · 34 enrolled · China
  3. Jul 21, 2025ARTBIO's first study: phase 1 study in Prostatic NeoplasmsNew to ARTBIOARTBIO · NCT07214961 · 80 enrolled · United States

Ahead

  1. Nov 3, 2027Primary completion: phase 1 study in Prostatic NeoplasmsARTBIO · NCT07214961

TargetBeta

FOLH1 →read by rule
“This Phase 1 study will evaluate the safety, tolerability, and preliminary effectiveness of AB001, an alpha-emitting radioligand targeting prostate-specific membrane antigen (PSMA), in patients with advanced prostate cancer who are either 177Lu-PSMA naïve or experienced.”study text, by rule · the study

Other programs on FOLH1

ProgramCompanyFurthest phaseStudies
flotufolastat F 18ruleBraccophase 47
piflufolastatruleLantheusphase 45
abefolastat tesaroxetan CU-64ruleclarity-pharmaceuticals-ltdphase 35
gallium 68 PSMA-11ruleNovartisphase 34
Lutetium Lu 177 Ludotadipeprulefuturechemphase 33
Anti-PSMA/Anti-CD28 Bispecific Antibody JNJ-87189401Johnson & Johnsonphase 32
Lutetium Lu 177 NYM032ruleNorroy Biosciencephase 32
actinium AC-225 vipivotide tetraxetanNovartisphase 32
HRS-4357Jiangsu HengRui Medicinephase 32
zadavotide guraxetanAstraZenecaphase 24
olsutamigruleRegeneron Pharmaceuticalsphase 22
SHR-4394Jiangsu HengRui Medicinephase 22

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07214961Prostatic Neoplasms · United States1Active, not recruitingARTBIONov 3, 202780
NCT03997734Chronic Low Back Pain · China1CompletedFrontier BiotechnologiesNov 11, 201934
NCT02436824Chronic Low Back Pain · United States2CompletedFrontier BiotechnologiesJul 2015146

How it is read

Names in the registry

  • “AB001”, 2 entries
  • “AB001 patch”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.